Protein / target
Thyroid hormone receptor beta
Protein at a glance
Biological role
Sequence-specific double-stranded DNA binding
Primary system
Endocrine & metabolic
Strongest disease association
glycogen storage disease due to glycogen branching enzyme deficiency
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
8 approved · 2 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine
Subcellular location
Domains and Gene Ontology detail (26)Hide
Domains & features
Gene Ontology
- Cchromatin
- Cnuclear body
- Cnucleoplasm
- Cnucleus
- CRNA polymerase II transcription regulator complex
- Fchromatin DNA binding
- FDNA binding
- FDNA-binding transcription factor activity
- FDNA-binding transcription factor activity, RNA polymerase II-specific
- Fenzyme binding
- Fnuclear receptor activity
- FRNA polymerase II cis-regulatory region sequence-specific DNA binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Transcriptional regulation
- ·Nuclear hormone receptor that can act as a repressor or activator of transcription. High…
- ·RNA polymerase II transcription regulator complex
- ·DNA-binding transcription factor activity
- ·DNA-binding transcription factor activity, RNA polymerase II-specific
Nuclear receptor signalling
- ·DNA-binding transcription factor activity
- ·DNA-binding transcription factor activity, RNA polymerase II-specific
- ·nuclear receptor activity
- ·Nuclear Receptor transcription pathway
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Thyroid hormone receptor beta-1 agonist
Appears in clinical studies involving metabolic dysfunction-associated steatotic liver disease, cirrhosis of liver, metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatohepatitis
Thyroid hormone receptor agonist
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 3,589 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 10 total
thyrotoxicosis · Allan-Herndon-Dudley syndrome · Allan-Herndon-Dudley syndrome
hypothyroidism · hypothyroidism · Shock
cardiovascular disorder
hypothyroidism · differentiated thyroid carcinoma · myxedema
hypothyroidism · congestive heart failure · bipolar disorder
differentiated thyroid carcinoma · hypothyroidism · thyroid cancer
cardiovascular disorder · Hypercholesterolemia · Hypercholesterolemia
metabolic dysfunction-associated steatotic liver disease · cirrhosis of liver · metabolic dysfunction-associated steatotic liver disease
familial hyperlipidemia · Hypercholesterolemia · fatty liver disease
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Label change
Label change: RESMETIROM (NDA217785)
- Label change
Label change: RESMETIROM (NDA217785)
- Label change
Label change: RESMETIROM (NDA217785)
- Label change
Label change: RESMETIROM (NDA217785)
- Regulatory approval
Approval: Rezdiffra (EMA)
- New publicationThyroid hormone and the Liver.
- New publicationHepatic thyroid hormone receptor-β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis.
- New publicationThyroid hormone receptor-β analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
- New publicationPrevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction-associated steatotic liver disease: An observational study.
- New publicationThyroid Hormone Homeostasis in Levothyroxine-treated Patients: Findings From ELSA-Brasil.
- New publicationThe first MASH drug therapy on the horizon: Current perspectives of resmetirom.
- New publicationResmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.